StockWatch
·

Wellgistics Health, Inc. Q3 FY25 Results

WGRXQ3 FY25 Results
Filing
MetricValue ($ M)vs Q2 FY25
Revenue3.0161.4%
Total Income3.0161.4%
Expenditure34.56160.1%
PBT-34.32414.5%
Net Profit-34.32414.5%
OPM—
NPM—
EPS-0.46318.2%
View full financials

Wellgistics Health Reports Third Quarter 2025 Financial Results

04 May 2026 · 4 May, 7:05 am

Summary

Wellgistics Health reported its financial results for the third quarter of 2025, which ended on September 30, 2025. The company experienced a net operating loss of $33.878 million, with a net loss per share of $0.46. The company is focusing on the launch of Brenzavvy® and is in discussions to complete a license agreement for its blockchain strategy. The acquisition of Peek Healthcare Technologies has been terminated.

Key Highlights

  1. 1

    Wellgistics Health reported financial results for the period ended September 30, 2025.

  2. 2

    The company recorded a net operating loss of $33.878 million in the third quarter of 2025.

  3. 3

    Net loss per share in the third quarter of 2025 was $0.46 on 74.379 million weighted average shares outstanding.

  4. 4

    The company is focusing its sales team on the launch of Brenzavvy® for the Type 2 diabetes market.

  5. 5

    Wellgistics is in advanced discussions to complete the license agreement underpinning its blockchain smart contracts strategy with DataVault AI in Q4 2025 or Q1 2026.

  6. 6

    The company expects its first GLP-1 side effect product to launch in the first quarter of 2026.

  7. 7

    The acquisition of Peek Healthcare Technologies, Inc. has been terminated.

Management Comments

P

Prashant Patel

“The last 6 weeks have really allowed me to understand the different stages of development of the various parts of the business after I was reappointed as President and given the title of Interim-CEO on October 6, 2025,” said Prashant Patel, RPh, President and Interim-CEO of Wellgistics Health. “We have centered the primary focus of our sales team on the launch of Brenzavvy® for the Type 2 diabetes market. Type 2 diabetes affects over 33 million Americans2 with only a small portion of patients getting access a SGLT-2 inhibitor drug primarily to out-of-pocket cost constraints. We have developed a program to significantly reduce these out-of-pocket costs for patients using our EinsteinRx™ AI pharmacy hub software, and expect this product launch may contribute meaningfully to our future revenue growth if successfully commercialized. One of the brightest spots in my review has been the tremendous work done over the last 6 months by our technology team led by Chief Technology Officer Srini Kalla to finalize EinsteinRx and make it ready for launch. The ability of our tech team to help implement our software seamlessly for our clients will be crucial for our long-term success and I now have great confidence in Srini’s ability to meet the growth challenge we expect to face.” Mr. Patel continued, “While the third quarter saw significant equity-based expenses tied to the pre-IPO acquisition of our pharmaceutical distribution business unit, we have begun to rationalize our go forward approach and it will be centered on the staged integration of EinsteinRx throughout our customers’ value chains. As we prepare to move into 2026 when we intend to put EinsteinRx onto the PharmcyChain™ smart contracts platform we expect to create, we believe there is a meaningful opportunity to optimize the way healthcare information is processed, exchanged and validated. By giving us better data to feed into our models, we intend to further optimize outcomes for patients while delivering cost reduction for payers. We are in advanced discussions to to complete the license agreement underpinning our blockchain smart contracts strategy with DataVault AI (NASDAQ: DVLT) in the fourth quarter of 2025 or the first quarter of 2026 in order to secure the opportunity-enabling intellectual property protection around which we will execute upon our roadmap to disrupt healthcare through efficiency.” “While our primary business is in the $634 billion US prescription drug market3, an increasing portion of U.S. discretionary healthcare spend is going into the $2 trillion US Wellness Market4. Telehealth providers now account for 17% GLP-1 US prescriptions5, which created the rationale for our proposed acquisition of Kare Hub Rx for its optimized ‘plug & play’ telepharmacy integration software that seamlessly allows telehealth providers to route prescriptions through our online pharmacy.” “In order to create a competitive edge in our GLP-1 offering business to pharmacies and telehealth companies, in March we partnered with Tollo Health to provide prescription-complementary products to address major GLP-1 side effects with their products soon becoming commercially available in the United States. The GLP-1 drug market currently sits at $53 billion annually according to Grandview Research and expected to reach $156 billion by 20306, currently dominated by Eli Lilly and Novo Nordisk, with various injection and oral formulations that all carry muscle loss side effects. Our goal is to eventually offer all GLP-1 drugs to pharmacy clients and through our online pharmacy at competitive prices, while selling cash-pay side effect-mitigating medical foods that we believe provide a more comprehensive solution than our competitors, while increasing margins per GLP-1 prescription.” “We expect our first GLP-1 side effect product that helps to mitigate muscle loss will launch in the first quarter of 2026. Additionally, we have begun distributing 3CL protease inhibitor cleansing supplement Tollovid™ targeting Long COVID to certain physicians. In 2024, the CDC reported that over 17 million Americans were living with Long COVID7. We expect certain Long COVID clinicians to begin making Tollovid available for their patients this month. We also plan to launch the first natural antiviral combo Tollovid and Galectovid™ to pharmacies after Thanksgiving. We intend to expand our prescription drug catalog to include drugs frequently prescribed for Long COVID in order to develop a full package for pharmacies.” Mr. Patel completed, “Lastly, the previously disclosed acquisition of Peek Healthcare Technologies, Inc. has been terminated.”

Informational and educational content only. Not investment advice.